RMD241220C230000
- 8.50
- +1.87+28.21%
ResMed Newsroom
Stifel Maintains ResMed(RMD.US) With Hold Rating, Maintains Target Price $250
Stifel Initiates ResMed at Hold With $250 Price Target
ResMed Analyst Ratings
Stifel Initiates ResMed(RMD.US) With Hold Rating, Announces Target Price $250
Analysts' Top Healthcare Picks: DocGo (DCGO), Resmed (RMD)
BofA Securities Maintains ResMed(RMD.US) With Buy Rating, Announces Target Price $270
A Quick Look at Today's Ratings for ResMed(RMD.US), With a Forecast Between $245 to $283
J.P. Morgan Sticks to Its Buy Rating for Resmed (RMD)
J.P. Morgan Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
ResMed Price Target Raised to $266.00/Share From $251.00 by Keybanc
ResMed Is Maintained at Overweight by Keybanc
Wolfe Research Adjusts Price Target on ResMed to $190 From $180
A Quick Look at Today's Ratings for ResMed(RMD.US), With a Forecast Between $283 to $283
ResMed Analyst Ratings
Resmed (RMD) Gets a Hold From Needham
ResMed Price Target Raised 4.3% to A$37.80/Share by Macquarie
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Abbott Laboratories (ABT)
BofA Securities Maintains ResMed(RMD.US) With Buy Rating, Announces Target Price $270
J.P. Morgan Maintains ResMed(RMD.US) With Buy Rating, Maintains Target Price $240
Mizuho Securities Maintains ResMed(RMD.US) With Buy Rating, Maintains Target Price $250